Follicular Lymphoma
From the Journals
Frontline rituximab shows long-term success in indolent lymphoma
A study with 10-year follow-up data suggests that chemotherapy can be delayed in symptomatic indolent lymphoma patients.
News
FDA lifts partial hold on tazemetostat trials
The partial hold that paused U.S.-based enrollment in clinical trials of tazemetostat has been lifted.
News
FDA approves new drug for CLL/SLL and follicular lymphoma
Duvelisib (Copiktra) has full approval to treat CLL/SLL and accelerated approval to treat FL.
News
Risks of watchful waiting in follicular lymphoma
A subset of follicular lymphoma (FL) patients managed with watchful waiting are vulnerable to organ dysfunction and transformation, according to...
From the Journals
Be wary of watchful waiting in follicular lymphoma
Management changes may be warranted.
Latest News
Novartis nabs first CAR T approval in Canada
Health Canada has approved its first chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel (Kymriah).
News
First CAR T-cell therapy approved in Canada
Health Canada has authorized use of tisagenlecleucel (Kymriah™), making it the first chimeric antigen receptor (CAR) T-cell therapy to receive...
News
Regimens produce similar results in FL
Rituximab plus lenalidomide had efficacy similar to that of rituximab plus chemotherapy in the treatment of follicular lymphoma (FL) in a phase 3...
From the Journals
Rituximab/lenalidomide similar to rituximab/chemotherapy for follicular lymphoma
Although the efficacy was similar, safety differed between the two regimens.
Feature
New BTK inhibitor under review in China
Zanubrutinib is being reviewed for treatment of relapsed/refractory mantle cell lymphoma.
News
EC approves CAR T-cell therapy for DLBCL, PMBCL
The European Commission (EC) has approved the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (Yescarta®) to treat two...